Companion Diagnostics Market Forecasts to 2030 – Global Analysis By Product (Kits & Reagents and Assays), Indication (Leukaemia, Melanoma, Cancer, Neurological Disorders, Cardiovascular Diseases, Infectious Diseases and Other Indications), Technology, End

Companion Diagnostics Market Forecasts to 2030 – Global Analysis By Product (Kits & Reagents and Assays), Indication (Leukaemia, Melanoma, Cancer, Neurological Disorders, Cardiovascular Diseases, Infectious Diseases and Other Indications), Technology, End User and By Geography

According to Stratistics MRC, the Global Companion Diagnostics Market is accounted for $7.24 billion in 2023 and is expected to reach $18.81 billion by 2030 growing at a CAGR of 14.6% during the forecast period. A companion diagnostic is a test used to ensure the usage of a comparable biological product or medication is both safe and effective. These tests are typically used to diagnose cancer, neurological, cardiovascular and infectious diseases. In this, an appropriate medicine is recommended based on the detected biomarker. Based on a particular patient's reaction, these tests offer tailored treatment. When deciding whether to use targeted therapeutics, companion diagnostic exams (CDXs) are crucial.

According to Lung Cancer Research Foundation report 2022, an estimated 236,740 people were diagnosed with lung cancer in 2022 in the United States, leading to more demand for lung cancer companion diagnostics.

Market Dynamics:

Driver:

Growing requirements for specialized treatments

Since genetic sequencing and genomics have advanced, it is generally accepted that various individuals might respond to medications differently. The technique of giving ""the right drug, at the right time, at the right dose, for the right person"" can be advanced by having a better understanding of a person's genetic traits or biomarkers. In order to give focused therapeutics to the appropriate candidate, pharmaceutical and biopharmaceutical firms are continually working to adopt patient-selection diagnostic frameworks in the early phases of drug development. This helps the market's expansion to grow further.

Restraint:

The instance for insufficient reimbursement

Despite growing acceptability, there are no established criteria for determining how much should be paid for a companion diagnostic test. Payment is determined on a case-by-case basis. For inpatient and outpatient care, reimbursement is different. Diagnostics are primarily covered for the inpatient care system by diagnosis-related groups. The payment is made in accordance with the detailed list of services that can be reimbursed for outpatient care. Therefore, the absence of compensation and onerous rules restrain market expansion.

Opportunity:

Increasing prevalence of cancer

The increased trends in new instances of pancreatic, female breast, and colorectal cancer as well as the stagnation of myeloma, uterine, and kidney cancer are attributed to the rising prevalence of obesity, diabetes, and physical inactivity. Companion diagnostics have proven to be a crucial tool for the treatment of individual patients in the clinic as well as for the process of developing new drugs. Information from companion diagnostics is crucial for the safe and efficient use of targeted medicines. This diagnosis has several ambitious objectives. The market is growing because of its effective diagnosis, monitoring, screening, and prognosis.

Threat:

High cost of immunotherapy treatment

The high expense of immunotherapy has restricted general patient access even though it has showed tremendous promise in the treatment of cancer. The length of the course of therapy might be increased from five months to over three years if doctors decide that it is beneficial to combine medicines. In this instance, the cost increases as the duration increases. Each CAR T-cell therapy is customized for the patient, requiring significant lab resources. As a result, the price per patient for the medicine alone rises to around USD 60,000. Cancer immune therapies can be far more expensive than other treatment choices like chemotherapy or radiation therapy. Consequently, it is anticipated that the high cost of immune-oncology treatments would restrain their expansion.

Covid-19 Impact

Early detection of COVID-19 became crucial in the market since it may aid in people with the condition receiving the right care. The polymerase chain reaction (PCR) test employing nasopharyngeal swabs or other upper respiratory tract specimens, including throat swabs, was the most widely used and trustworthy method for the diagnosis of COVID-19. Polymerase chain reaction (PCR)-based diagnostics, then, became a key area of focus for treating the illness. The development of new biomarkers for various diseases, an increase in research and development of targeted therapies, an increase in demand for customized medicine with increased recognition in developing markets, and a higher number of unmet medical needs are all contributing factors fuelled the market growth.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to have a lucrative growth, due to the growing prevalence of lung cancer all around the world. When deciding whether to use targeted medicines to treat lung cancer, companion diagnostic tests (CDXs) are regarded as indispensable. Lung cancer patients who obtained companion diagnostics as part of their initial treatment had higher survival rates than patients who did not get screened. The increasing prevalence of non-small cell lung cancer (NSCLC), together with the acceleration of the development of oncology companion diagnostic tests for the condition, are expected to propel the segment's growth on a global scale.

The polymerase chain reaction (PCR) segment is expected to have the highest CAGR during the forecast period

The polymerase chain reaction (PCR) segment is anticipated to witness the fastest CAGR growth during the forecast period. The highly sensitive PCR method enables quick DNA amplification of a particular section. Using visual methods based on size and charge, PCR may detect and identify gene sequences by producing billions of copies of a certain DNA fragment or gene. It is a rapid diagnostic exam that takes 4 to 8 hours to complete. The category is growing as a consequence of its speedier results, efficient appropriate therapy, and anti-microbial resistance testing.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. United States is emerging as a major contributor in the region. The United States has begun to play a significant role in this region. The most common users of companion diagnostics in the US are those with chronic diseases. The market is expanding as a result of rising research activities employing companion diagnostic kits in this region as well as the rising number of healthcare organizations working on genomic databases created to comprehend the human genome.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the growing preference for personalized medicine and increasing collaboration among companies. The region's highest market share is held by Germany and France. The market demand is being further fuelled by the region's growing medical tourism industry as well as the region's expanding senior population who are more susceptible to cancer and neurological illnesses.

Key players in the market

Some of the key players profiled in the Companion Diagnostics Market include Abbott, Agendia N.V, Agilent Technologies, ARUP Laboratories, Inc., Biogenex Laboratories, Inc., Dako, Inc., Roche Molecular Systems, Inc., Foundation Medicine, Inc., GE Healthcare, Genomic Health, Illumina, Inc., Genetron Holdings Limited, Labcorp Drug Development, Leica Biosystems, Life Technologies Corporation, MolecularMD Corporation, Myriad Genetic Laboratories, Inc., Ventana Medical Systems, Inc., Exact Sciences Corporation and Qiagen.

Key Developments:

In January 2023, Thermo Fisher Scientific partners with Astrazeneca to develop solid tissue and blood-based companion diagnostic test for tagrisso. The collaboration will leverage the Oncomine Dx Express Test* on the Genexus Dx System*, a fully-integrated next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that economically delivers results in as little as 24 hours to bring test results to clinicians and patients faster.

In February 2022, Genetron Holdings Limited, a leading precision oncology platform company in China specializing in molecular profiling tests, early cancer screening products, and companion diagnostics development, entered a collaboration agreement with HUTCHMED (China) Limited to develop a companion diagnostic (CDx).

Products Covered:
• Kits & Reagents
• Assays

Indications Covered:
• Leukaemia
• Melanoma
• Cancer
• Neurological Disorders
• Cardiovascular Diseases
• Infectious Diseases
• Other Indications

Technologies Covered:
• Real-time PCR (RT-PCR)
• Polymerase Chain Reaction (PCR)
• Next-generation Sequencing
• In Situ Hybridization (ISH)
• Immunohistochemistry (IHC)
• Gene Sequencing
• Other Technologies

End Users Covered:
• Contract Research Organizations
• Pharmaceutical & Biopharmaceutical Companies
• Reference Laboratories
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements



Companies Mentioned
Abbott
Agendia N.V
Agilent Technologies
ARUP Laboratories, Inc.
Biogenex Laboratories, Inc.
Dako, Inc.
Roche Molecular Systems, Inc.
Thermo Fisher Scientific
GE Healthcare
Genomic Health
Illumina, Inc.
Genetron Holdings Limited
Labcorp Drug Development
Leica Biosystems
Life Technologies Corporation
MolecularMD Corporation
Myriad Genetic Laboratories, Inc.
Ventana Medical Systems, Inc.
Exact Sciences Corporation
Qiagen